VTX3232 + semaglutide

VTX3232 + semaglutide is an investigational drug combination currently being studied for the treatment of obesity. VTX3232 is a novel agent under development by Ventyx Biosciences, with preclinical data showing improvements in body weight, systemic inflammatory biomarkers, and cardiometabolic parameters in models of diet-induced obesity. Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist approved for type 2 diabetes and chronic weight management; it works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering glucagon secretion. The combination aims to leverage the complementary mechanisms of both agents to enhance weight loss and metabolic benefits. Clinical trials are ongoing to evaluate safety and efficacy in obese patients[1][2][3][4][5][6][7][8].

Other names

none